MARKET

ORIC

ORIC

Oric Pharmaceuticals, Inc.
NASDAQ
13.75
+0.29
+2.12%
After Hours: 14.00 +0.25 +1.82% 17:37 03/28 EDT
OPEN
13.52
PREV CLOSE
13.47
HIGH
14.07
LOW
13.19
VOLUME
725.53K
TURNOVER
0
52 WEEK HIGH
16.65
52 WEEK LOW
4.690
MARKET CAP
926.42M
P/E (TTM)
-7.0257
1D
5D
1M
3M
1Y
5Y
ORIC Pharmaceuticals: Rally Seems Overdone
ORIC Pharmaceuticals, Inc. Has three programs in the clinic. The company focuses on developing therapies to counter resistance mechanisms in cancer. ORIC's stock has seen significant gains since releasing promising data from its ORIC-114 program. The brain-penetrant candidate induced multiple partial responses in NSCLC patients. The firm has a strong balance sheet with approximately $350 million in cash.
Seeking Alpha · 51m ago
Oric Pharmaceuticals Price Target Cut to $18.00/Share From $19.00 by JP Morgan
Dow Jones · 1d ago
Oric Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $18
Benzinga · 1d ago
Weekly Report: what happened at ORIC last week (0318-0322)?
Weekly Report · 4d ago
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
Rosenblatt boosted the price target for Micron Technology, Inc. (NASDAQ:MU) from $140 to $225 on Wednesday. TD Cowen raised the pricetarget for Broadcom Inc. From $1,400 to $1.5 million. Needham increased the price targets for Alight and Crocs. Five Below shares gained 1.1%.
Benzinga · 03/21 13:15
Oric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming Catalysts
TipRanks · 03/21 10:27
Oric Pharmaceuticals Price Target Raised to $21.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 03/21 10:25
More
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

Webull offers ORIC Pharmaceuticals Inc stock information, including NASDAQ: ORIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORIC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORIC stock methods without spending real money on the virtual paper trading platform.